RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN319.98m
- PLN332.91m
- PLN62.25m
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project
Brief: Ryvu Therapeutics Says 'PERO' Project Recommended For Funding By National Centre For Research And Development
Brief: Ryvu Therapeutics Q3 Net Loss At 24.7 Million Zlotys
Brief: Ryvu Therapeutics Q2 Net Loss At 33.7 Million Zlotys
Brief: Ryvu Therapeutics Says RVU120 To Be Tested In Phase I Study Run By IPCZD
Brief: Ryvu Therapeutics Signs Deal To Support Clinical Trials For BioNTech’s Investigational Cancer Immunotherapies In Poland
Brief: Ryvu Therapeutics Q1 Net Loss At 25.3 Mln Zlotys
Brief: Ryvu Therapeutics Signs Grant Deal With Medical Research Agency
Brief: Ryvu Therapeutics Withdraws From Grant Agreement To Identify PRMT5 Inhibitor Markers
Brief: Ryvu Therapeutics FY Net Loss At 111.4 Mln Zlotys
Brief: WSE Says Zabka To Join WIG20 Index
Brief: Ryvu Therapeutics To Lay Off Up To 145 Employees
Brief: Ryvu Therapeutics Announces Strategic Reorganization To Extend Cash Runway
Brief: Ryvu Therapeutics Signs Funding Deal With Malopolska Centre For Entrepreneurship
Brief: Ryvu Therapeutics Says Its Project Recommended For Funding By Medical Research Agency
Brief: Ryvu Therapeutics Says Its Project Recommended For Funding By Medical Research Agency